ATLANTA, Jan. 25 /PRNewswire/ -- Alimera Sciences Inc., an ophthalmic pharmaceutical company, today announced the appointment of Richard S. Eiswirth as the company’s chief financial officer. Active in Atlanta’s business circles for more than 15 years, Eiswirth’s portfolio includes entrepreneurial and consulting experience with numerous key business transactions including mergers, acquisitions and initial public offerings.
Eiswirth takes the financial helm of Alimera Sciences as Daniel White, co- founder and former vice president of finance and corporate development, transitions to vice president of corporate development. In this position, White is developing corporate growth opportunities, international markets and strategic partnerships. White was instrumental in securing Alimera’s two major financing rounds, resulting in more than $60 million in capital.
“As Alimera Sciences’ revenue sources and business development activities expand, it is necessary to delineate financial and development responsibilities,” said Dan Myers, Alimera Sciences chief executive officer. “I believe that Rick’s extensive financial management expertise is a great fit to assist Alimera Sciences in successfully implementing its growth strategy.”
Founder of two consulting practices, Brand Ignition Group and Black River Holdings, Inc., and former CFO and senior executive vice president of Netzee, Inc., Eiswirth also served as a senior manager on Arthur Andersen’s audit and business advisory team.
Eiswirth is a graduate of Wake Forest University and serves on the board of directors for Norcross-based Color Imaging Inc.
About Alimera Sciences Inc.
Alimera Sciences Inc. specializes in the development and commercialization of over-the-counter and prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences’ products address both the anterior (front) and posterior (back) segments of the eye. In August 2004, Alimera Sciences unveiled Soothe(R), the market’s first multi-dose, emollient-based artificial tear product, and in October 2005 initiated a Phase III clinical trial to study diabetic macular edema (DME) patients treated using Medidur(TM) with fluocinolone acetonide, the company’s pharmacologic treatment for DME.
http://www.alimerasciences.com
Alimera Sciences Inc.
CONTACT: Mike Greenwell of Fleishman Hillard, +1-404-739-0155, orgreenwem@fleishman.com
